Request for Proposals – FNIH Cancer Steering Committee Project Concepts for Novel Biomarker Platforms to Support Novel Tissue Imaging, Remote Sensing, and Toxicity Challenges
Notice Number:

Key Dates

Release Date:

December 23, 2021

Related Announcements


Issued by

National Cancer Institute (NCI)


Solicitation Announcement

Requests for Proposal information and application forms can be found here:


The FNIH Biomarkers Consortium is issuing a Request for Proposals (RFP) for novel biomarker platforms to support the mission of the BC Cancer Steering Committee (CSC) High Content Data Integration Working Group (HCDI WG). The mission of the HCDI WG is to develop and support pilot projects that use emerging technology platforms with the potential to overcome limitations of established methodologies in the application of multi-dimensional biomarkers. The working group is focused on technologies that have the potential to address recognized clinical challenges, such as for development of tailored signatures for patient stratification, alternatives to solid biopsies, and advanced imaging technologies.

The HCDI WG invites investigative teams to submit brief project concept proposals for application of biomarker platforms to any of three clinical challenges given below. The working group is currently focused on identifying testable technical solutions with potential for commercialization that address these challenges. These proposals will be considered for funding under the BC precompetitive project model described in the Request for Proposals.

  • Challenge 1: Novel tissue imaging platforms to characterize the tumor and microenvironment, by providing insight into tumor heterogeneity and spatial relationships.
  • Challenge 2: Novel blood-based or remote sensing technologies that can be used to replace or augment solid tumor biopsies to enable meaningful clinical intervention opportunities (e.g., as an add-on and/or alternative tool to solid biopsies).
  • Challenge 3: Patient screening platforms to identify potentially predictive biomarkers associated with toxicities/adverse effects that commonly lead to discontinuation of cancer clinical trial participation, such as thrombocytopenia, liver toxicity, neutropenia and gastrointestinal toxicity. Focus on platforms that can be integrated into trial protocols and emulate the complex interactions in the organ of interest.

A pre-application webinar will provide information about the Biomarkers Consortium project development process and opportunity for Q&A. Details can be found here:


Please direct all inquiries to:

Dana Connors
FNIH Biomarkers Consortium